Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVJNFI)

• Drug Name: Spermidine Drug Info
• Synonyms: Spermidin; UNII-U87FK77H25; BRN 1698591; AI3-26636; EINECS 204-689-0; CHEMBL19612; CHEBI:16610; ATHGHQPFGPMSJY-UHFFFAOYSA-N; U87FK77H25; MFCD00008229; Spermidine hydrochloride; NSC528399; 1pot; Aminopropylbutandiamine; N-(4-Aminobutyl)-1,3-diaminopropane; Spectrum_000005; Tocris-0959; ACMC-20ajn3; AC1L1AQB; Spectrum2_000874; Spectrum3_000977; Spectrum4_001101; Spectrum5_001561; Lopac-S-2501; Biomol-NT_000212; bmse000116; bmse000951; bmse000955; Spermidine 0.1 M solution; Lopac0_001047; SCHEMBL15618; BSPBio_002613; KBioGR_001542; KBioSS_000345; 4-04-00-01300 (Beilstein Handbook Reference); DivK1c_001007; SPBio_000947; Spermidine, > =99% (GC); Spermidine, analytical standard; BPBio1_001276; GTPL2390; DTXSID4036645; CTK3J1693; KBio1_001007; KBio2_000345; KBio2_002913; KBio2_005481; KBio3_001833; MolPort-001-761-230; NINDS_001007; HY-B1776; ZINC1532612; BDBM50009353; PA(34); N-(3-Aminopropyl)-4-aminobutylamine; AKOS006222987; CCG-205124; DB03566; MCULE-8096530192; RTR-003757; SDCCGMLS-0066822.P001; IDI1_001007; NCGC00015937-01; NCGC00015937-02; NCGC00015937-03; NCGC00015937-04; NCGC00015937-05; NCGC00024903-01; NCGC00024903-02; NCGC00024903-03; AJ-26792; AN-22947; LS-45643; M923; NCI60_004294; SC-69371; DB-026892; TR-003757; CS-0013804; FT-0629162; ST24048721; ST45025991; C00315; 124S209; SR0

Indication

Disease Entry	ICD 11	Status	REF
Plaque psoriasis	EA90.0	Phase 3	[1]
Rheumatoid arthritis	FA20	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 1102
  ChEBI ID: CHEBI:16610
  CAS Number: CAS 124-20-9
  TTD Drug ID: DMVJNFI
  VARIDT Drug ID: DR01250
  INTEDE Drug ID: DR1504

Molecule-Related Drug Atlas

Drug(s) Targeting Cytoplasmic thioredoxin reductase (TXNRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fotemustine	DMV62ED	Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Golden phosphorous acetyletic compound 2	DMYJ15A	N. A.	N. A.	Patented	[8]
Terpyridineplatinum(II) complexe 3	DM54EFD	N. A.	N. A.	Patented	[8]
Terpyridineplatinum(II) complexe 4	DMOV86T	N. A.	N. A.	Patented	[8]
Golden phosphorous acetyletic compound 1	DMVAKUI	N. A.	N. A.	Patented	[8]
Acyl oxymethyl acrylamide ester derivative 1	DMXTUE1	N. A.	N. A.	Patented	[8]
PMID27977313-Compound-18	DMIA3GH	N. A.	N. A.	Patented	[8]
Triazole gold complexe 1	DMCWES7	N. A.	N. A.	Patented	[8]
4-aryl quinol derivative 2	DM7TW5Z	N. A.	N. A.	Patented	[8]
PMID27977313-Compound-46	DMGF04T	N. A.	N. A.	Patented	[8]

Drug(s) Transported By Organic cation transporter 1 (SLC22A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[9]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[10]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[11]
Oxaliplatin	DMQNWRD	Adenocarcinoma	2D40	Approved	[12]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[4]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[13]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[14]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[15]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[16]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[17]

Drug(s) Transported By MFS-type transporter SLC18B1 (SLC18B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[3]

Drug(s) Metabolized By Putrescine acetyltransferase (SSAT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[18]
N1-(2-aminoethyl)ethane-1,2-diamine	DM6HM5S	Discovery agent	N.A.	Investigative	[18]
Ethylene diamine	DMBULX4	Tuberculosis	1B10-1B1Z	Investigative	[18]
Propandiamine	DMQ9USH	N. A.	N. A.	Investigative	[18]

Drug(s) Affected By Beta-2 adrenergic receptor (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[19]
Bambuterol	DMKLSHF	Asthma	CA23	Approved	[20]
Terbutaline	DMD4381	Asthma	CA23	Approved	[21]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[22]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[23]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[24]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[25]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[26]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[27]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[28]

Drug(s) Affected By Beta-1 adrenergic receptor (ADRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dobutamine	DMD1B8Z	Heart failure	BD10-BD13	Approved	[29]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[30]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[24]
Vortioxetine	DM6F1PU	Major depressive disorder	6A70.3	Approved	[31]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[32]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[33]
Labetalol	DMK8U72	Hypertension	BA00-BA04	Approved	[34]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[35]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[36]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[37]

Drug(s) Affected By Sodium/potassium-transporting ATPase subunit gamma (FXYD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[38]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[39]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[40]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[32]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[41]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[42]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[43]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[44]
2-deoxyglucose	DMIAHVU	Solid tumour/cancer	2A00-2F9Z	Approved	[7]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[45]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytoplasmic thioredoxin reductase (TXNRD1)	TTR7UJ3	TRXR1_HUMAN	Inhibitor	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
MFS-type transporter SLC18B1 (SLC18B1)	DTOFXP5	S18B1_HUMAN	Substrate	[3]
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Putrescine acetyltransferase (SSAT1) Main DME	DEMWO83	SAT1_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Beta-1 adrenergic receptor (ADRB1)	OTQBWN4U	ADRB1_HUMAN	Protein Interaction/Cellular Processes	[6]
Beta-2 adrenergic receptor (ADRB2)	OTSDOX4Q	ADRB2_HUMAN	Protein Interaction/Cellular Processes	[6]
Sodium/potassium-transporting ATPase subunit gamma (FXYD2)	OT97BX21	ATNG_HUMAN	Regulation of Drug Effects	[7]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [3] Identification of a mammalian vesicular polyamine transporter. Sci Rep. 2014 Oct 30;4:6836.
• [4] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [5] The use of novel C-methylated spermidine derivatives to investigate the regulation of polyamine metabolism. J Med Chem. 2011 Jul 14;54(13):4611-8.
• [6] Functional effects of polyamines via activation of human 1- and 2-adrenoceptors stably expressed in CHO cells. Pharmacol Rep. 2010 Jul-Aug;62(4):696-706. doi: 10.1016/s1734-1140(10)70327-3.
• [7] Heterologous expression of the Na(+),K(+)-ATPase gamma subunit in Xenopus oocytes induces an endogenous, voltage-gated large diameter pore. J Physiol. 2001 Sep 1;535(Pt 2):407-17.
• [8] Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
• [9] Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
• [10] Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
• [11] Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
• [12] Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
• [13] Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
• [14] Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
• [15] Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
• [16] Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
• [17] Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
• [18] Mechanistic and structural analysis of human spermidine/spermine N1-acetyltransferase. Biochemistry. 2007 Jun 19;46(24):7187-95.
• [19] Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
• [20] Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
• [21] Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
• [22] beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
• [23] Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
• [24] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [25] Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease. Br Heart J. 1992 May;67(5):419-20. doi: 10.1136/hrt.67.5.419-b.
• [26] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [27] Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
• [28] Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol. 2007 Mar 15;73(6):814-23. doi: 10.1016/j.bcp.2006.11.022. Epub 2006 Dec 1.
• [29] The Arg389Gly 1-adrenoceptor gene polymorphism influences the acute effects of -adrenoceptor blockade on contractility in the human heart. Clin Res Cardiol. 2011 Aug;100(8):641-7. doi: 10.1007/s00392-011-0288-1. Epub 2011 Feb 11.
• [30] Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor. Mol Pharmacol. 2003 Jun;63(6):1312-21. doi: 10.1124/mol.63.6.1312.
• [31] Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12.
• [32] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [33] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [34] Preclinical pharmacologic properties of dilevalol, an antihypertensive agent possessing selective beta 2 agonist-mediated vasodilation and beta antagonism. Am J Cardiol. 1989 Jun 5;63(19):3I-6I. doi: 10.1016/0002-9149(89)90120-3.
• [35] Effects of chronic amiodarone treatment on human myocardial beta adrenoceptor density and adenylate cyclase response. Cardiovasc Res. 1991 Jun;25(6):503-9. doi: 10.1093/cvr/25.6.503.
• [36] Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig. 2005 Oct;12(7):e55-67.
• [37] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [38] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [39] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [40] Evidence for a role of claudin 2 as a proximal tubular stress responsive paracellular water channel. Toxicol Appl Pharmacol. 2014 Sep 1;279(2):163-72.
• [41] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [42] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [43] Drinking-water arsenic exposure modulates gene expression in human lymphocytes from a U.S. population. Environ Health Perspect. 2008 Apr;116(4):524-31. doi: 10.1289/ehp.10861.
• [44] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [45] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.